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Background: Current biochemical indicators cannot discriminate between parenchymal, biliary, vascular, and neoplastic
hepatobiliary diseases. MicroRNAs are promising new biomarkers for hepatobiliary disease in humans and dogs.
Objective: To measure serum concentrations of an established group of microRNAs in dogs and to investigate their
concentrations in various types of hepatobiliary diseases.
Animals: Forty-six client-owned dogs with an established diagnosis of hepatobiliary disease and stored serum samples
and eleven client-owned healthy control Labrador Retrievers.
Methods: Retrospective study. Medical records of dogs with parenchymal, biliary, vascular, or neoplastic hepatobiliary
diseases and control dogs were reviewed. Concentrations of miR-21, miR-122, miR-126, miR-148a, miR-200c, and miR-222
were quantiﬁed in serum by real-time polymerase chain reaction.
Results: No diﬀerent microRNA concentrations were found in the adenoma and congenital portosystemic shunt groups.
In all other diseases, miR-122 concentrations were elevated with the highest concentration in the mucocele group (267-fold,
CI: 40–1,768, P < .001). In dogs with biliary diseases, miR-21 and miR-222 were only increased in dogs with mucoceles (26-
fold, CI: 5–141, P = .005 and 13-fold, CI: 2–70, P = .025, respectively). Uniquely increased microRNAs were found in the
hepatocellular carcinoma group (miR-200c, 35-fold increase, CI: 3–382, P = .035) and the chronic hepatitis group (miR-126,
22-fold increase, CI: 5–91, P = .002).
Conclusions and Clinical Importance: A microRNA panel consisting of miR-21, miR-122, miR-126, miR-200c, and miR-222
can distinguish between parenchymal, biliary, and neoplastic hepatobiliary diseases. Serum microRNA proﬁling is a promising
new tool that might be a valuable addition to conventional diagnostics to help diagnose various hepatobiliary diseases in dogs.
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Hepatobiliary diseases are commonly encountered indogs and can be divided into 4 main groups:
parenchymal, biliary, vascular, or neoplastic diseases.1
In many cases, clinical signs of hepatobiliary diseases
are nonspeciﬁc. To establish a tative diagnosis, bio-
chemical blood parameters are used as a ﬁrst step in
most cases. Several laboratory tests can be used to eval-
uate hepatocellular damage and hepatic function. The
most commonly used biochemical indicators of
hepatobiliary injury are alanine aminotransferase
(ALT), alkaline phosphatase (AP), aspartate amino-
transferase (AST), and gamma-glutamyltransferase
(GGT).2 To conﬁrm the existence of signiﬁcant hepatic
impairment, liver function tests can be performed,
including measurements of bilirubin, bile acids (BA),
and ammonia levels in blood.3,4 With the exception of
some vascular hepatic diseases (i.e, congenital portosys-
temic shunts),5 biochemical indicators function at best
establishing the presence of hepatobiliary disease but
are usually not suﬃcient to specify the underlying
disease.
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AH acute hepatitis
ALT alanine aminotransferase
AP alkaline phosphatase
AST aspartate aminotransferase
BA bile acids
BI other biliary diseases; cholangitis or extrahepatic bile
duct obstruction
CDmiR cholangiocyte-derived microRNA
CH chronic hepatitis
CI conﬁdence interval
CPSS congenital portosystemic shunts
GGT gamma-glutamyltransferase
HCA hepatocellular adenoma
HCC hepatocellular carcinoma
HDmiR hepatocyte-derived microRNA
L lymphoma
MU mucocele
NL normal liver
RT-PCR real-time polymerase chain reaction
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A thorough and extensive diagnostic workup includ-
ing imaging techniques, cytology and culture of bile,
and cytologic and histopathologic evaluation of liver
biopsies is usually necessary to establish a deﬁnitive
diagnosis.1 A relatively noninvasive sensitive and speci-
ﬁc blood-based biomarker proﬁle that can diﬀerentiate
between various types of hepatobiliary disease can
potentially restrict or specify follow-up tests and be a
valuable addition in current diagnostic workup
protocols.
Mature microRNAs are a class of small noncoding
RNAs that are important regulators of posttranscrip-
tional gene expression.6 With critical functions in the
regulation of multiple aspects of hepatic development,
microRNAs have recently emerged as promising and
stable candidate biomarkers for a variety of hepatobil-
iary diseases in humans.7–9 Several hepatocyte-derived
microRNAs (HDmiRs) and cholangiocyte-derived
microRNAs (CDmiRs) have been shown to be sensi-
tive and stable candidate biomarkers in human patients
with acute or chronic liver injury caused by various
etiologies, for example drug- or hepatitis C virus-
induced liver injury.10–12 Studies focusing on neoplastic
diseases demonstrated diﬀerent serum concentrations
of several microRNAs in human patients with intra-
hepatic cholangiocarcinoma or hepatocellular carci-
noma versus normal patients.13–15 The ﬁrst aim of this
exploratory study was to evaluate whether the concen-
trations of a selected group of hepatocyte-derived,
cholangiocyte-derived, and oncogenic microRNAs,
based on the current human literature, were measur-
able in serum of dogs with parenchymal, biliary, vas-
cular, or neoplastic hepatobiliary diseases. Our second
aim was to explore the possibility of using a serum
microRNA proﬁle as a biomarker for canine hepato-
biliary diseases by providing an overview of serum
concentrations of select microRNAs in dogs with
parenchymal, biliary, vascular, or neoplastic hepatobil-
iary diseases.
Materials and Methods
Animals
Medical records of dogs referred to the Department of Clinical
Sciences of Companion Animals, Faculty of Veterinary Medicine,
Utrecht University, between 1999 and 2014 were reviewed. Data
concerning signalment, physical examination, biochemical, ultra-
sonographic, cytologic, and histopathologic ﬁndings were
retrieved from the medical records. At time of admission, all
dogs underwent physical examination, a biochemistry panel (in-
cluding at least ALT, AP, and BA), and ultrasonographic exami-
nation of the hepatobiliary system. Of the 4 main groups of
hepatic diseases, that is, parenchymal, biliary, vascular, or neo-
plastic, 8 subgroups were distinguished in this study. Parenchymal
diseases included dogs with acute hepatitis (AH) or chronic hep-
atitis (CH). Biliary diseases were divided into mucoceles (MU)
and dogs with cholangitis (lymphocytic or destructive) or extra-
hepatic bile duct obstruction, the latter two termed “other biliary
diseases” (BI). The vascular disease group solely contained dogs
with congenital portosystemic shunts (CPSS). The neoplastic dis-
eases group included dogs with hepatocellular adenomas (HCA),
hepatocellular carcinomas (HCC), and hepatic lymphoma (L).
The ﬁnal diagnosis of AH, CH, BI, HCA, and HCC was estab-
lished by the evaluation of a histologic liver biopsy. The presence
of L was established by histology or cytology. Diagnostic criteria
for MU included the typical appearance of an enlarged gallblad-
der with immobile, echogenic bile with a striated or stellate pat-
tern during ultrasonographic examination,16 histologically
conﬁrmed after surgical removal of the gall bladder, or both
modalities. The presence of CPSS was conﬁrmed either on sur-
gery or a CT-contrast study. All subgroups contained at least 5
conﬁrmed cases. Control dogs (normal liver group, NL) were
Labrador Retrievers, selected from the database from an ongoing
research program about copper-associated hepatitis of the Faculty
of Veterinary Medicine, Utrecht University.17 All control dogs
were clinically healthy Labrador Retrievers that underwent a liver
biopsy for screening for copper-associated hepatitis. The control
dogs had a normal biochemistry panel, unremarkable abdominal
ultrasound, and absence of hepatic disease on histopathologic
evaluation of a liver biopsy. Of all dogs included in the study,
clinical data as well as biological material (i.e, serum samples)
were stored until further analysis was performed. Abdominal
ultrasounds were performed by board-certiﬁed radiologists. His-
tology was evaluated by a board-certiﬁed veterinary pathologist
(GCMG) according to the World Small Animal Veterinary Asso-
ciation standards and who was unaware of the results of the
microRNA analysis at the time of histopathologic evaluation.1
All data were collected according to the Act on Veterinary Prac-
tice, as required under Dutch legislation, and all procedures were
known and approved by the Animal Welfare Body of the Univer-
sity of Utrecht.
RNA Isolation
Serum samples obtained at the time of diagnostic workup of
the dogs were stored at 20°C or 70°C until microRNA analy-
sis. Total RNA was extracted from 100 lL serum with a miR-
Neasy Serum/Plasma kit,a following the manufacturer’s
instructions. Brieﬂy, RNA was extracted from the serum by lysis
reagent (500 lL) and chloroform (100 lL). After centrifugation at
12,000 9 g for 15 minutes at 4°C, the aqueous phase was trans-
ferred to a fresh tube with 450 lL of ethanol. RNA was puriﬁed
on a RNeasy minElute spin columna and eluted in 14 lL RNase-
free water and stored at 20°C. Normalization was achieved by
adding 5.6 9 108 copies of synthetic C. elegans miR-39 spike-in
controla after the addition of lysis reagent, before the addition of
chloroform and the phase separation.
Reverse Transcription and Real-Time Polymerase
Chain Reaction (RT-PCR)
The miScript II Reverse Transcription kita was used to prepare
cDNA according to the manufacturer’s instructions. The obtained
cDNA was diluted to a total volume of 200 lL. Based on the cur-
rent human literature, the serum concentrations of miR-122 and
miR148a (HDmiRs in humans), miR-21 and miR-126 (oncogenic
miRs in human), and miR-200c and miR-222 (CDmiRs in
humans) were chosen to be measured in dogs with various hepatic
diseases.18–23 RT-PCR was performed with the miScript SYBR
Green PCR kit.a All PCRs were carried out in duplicate in a
CFX-384 Real-Time PCR detection system.b Each reaction con-
sisted of 5 lL 29 QuantiTect SYBR Green PCR Master Mix,
1 lL 109 universal primer, 1 lL 109 miR-speciﬁc primera, and
1 lL of the previously diluted cDNA. The total reaction volume
of each PCR was adjusted to 10 lL by adding 2 lL RNase-free
water. The concentrations of all microRNAs were quantiﬁed by
absolute quantiﬁcation via a standard curve, with quantities nor-
malized to the spike-in control.24
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Statistical Analysis
Data were summarized as median and range for summary
statistics of the study subjects. Linear regression was used with
miRNA serum concentrations as dependent variables and diagnos-
tic group as independent variable. Eight diseased groups (AH,
CH, BI, MU, CPSS, HCA, HCC, and L) were included, and the
normal liver group was used as the reference category. The natural
logarithm of the diﬀerent microRNAs was taken to ensure validity
of all models, which was checked by studying the residuals on nor-
mality and constant variance. P values were adjusted for multiple
comparisons by the Benjamini–Hochberg correction. Data were
analyzed by R statistics (version 3.1.2).c
Results
Dog Characteristics
Serum samples of 57 dogs were analyzed (11 healthy,
46 with hepatic disease). Dog characteristics including
sex, age, bile acids, and liver transaminases are summa-
rized in Table 1. Dogs from the hepatobiliary disease
groups consisted of crossbreeds (n = 9), Labrador
Retrievers (n = 6), English cocker spaniels (n = 6),
Golden Retrievers (n = 4), Cairn terriers (n = 3), Maltese
dogs (n = 2), miniature pinschers (n = 2), Scottish terriers
(n = 2), and one of each of the following breeds: Beagle,
Bernese mountain dog, Bouvier des Flandres, Cavalier
King Charles spaniel, Dobermann, German Shepherd,
Fox terrier, Munsterlander, Polish lowland sheepdog,
Shetland Sheepdog, Shih Tzu, and Tibetan terrier.
MicroRNA Serum Concentrations in Dogs with
Hepatic Disease
Full list of fold changes, conﬁdence intervals, and P
values of microRNA concentrations in dogs with vari-
ous hepatobiliary diseases relative to microRNA con-
centrations in the normal liver group are summarized in
supplementary Table 1. Except for miR-148a, all micro-
RNAs were higher in one or more disease groups
(Figs 1, 2) compared to the normal group. In dogs with
HCA and CPSS, none of the tested microRNAs were
higher compared to the normal liver group. Micro-
RNA-122 concentrations were increased in all
parenchymal diseases (AH, CH), biliary diseases (MU,
BI), and 2 neoplastic diseases (HCC, L) compared to
controls. miR-122 was the highest microRNA in the
MU group, with a 267-fold upregulation (CI: 40–1,768,
P < .001) compared to control.
The second most often increased microRNA was
miR-21. Compared to dogs with normal livers, miR-21
concentrations were increased in the MU, CH, HCC,
and L groups. In dogs with biliary diseases, miR-21 and
miR-222 were only increased in dogs with mucoceles
(26-fold, CI: 5–141, P = .005 and 13-fold, CI: 2–70,
P = .025, respectively), as dogs with cholangitis or
extrahepatic bile duct obstruction did not have
increased miR-21 or miR-222 concentrations. In dogs
with parenchymal diseases, miR-21 was only increased
in dogs with CH (19-fold, CI: 5–141, P = .005) and not
in dogs with AH. MicroRNA-222 was increased in dogs
with MU and HCC compared to normal dogs (13-fold,
CI: 2–70, P = .025 and 9-fold, CI: 2–42, P = .041,
respectively). Both miR-200c and miR-126 were
uniquely increased in one disease group. From all
microRNAs increased in the HCC group, miR-200c
had the highest concentrations, with a 35-fold increase
(CI: 3–383, P = .035), compared to the normal liver
group. With a 22-fold increase (CI: 5–91, P = .002),
miR-126 was only signiﬁcantly expressed in the CH
group.
Discussion
Results of this study demonstrate that a panel of dif-
ferent microRNAs in dogs with hepatobiliary disease
could be possibly used in the future as a diagnostic
marker for diﬀerent hepatobiliary diseases in dogs. Cur-
rent biochemical blood parameters of hepatobiliary
injury and dysfunction cannot discriminate between
most hepatobiliary diseases.4,25 The gold standard to
diﬀerentiate between these diseases is histopathologic
evaluation of liver biopsy specimens after ultrasono-
graphic examination of the liver and biliary tract sys-
tem.1 It would be of great value to use a relative
noninvasive biomarker to characterize the type of hepa-
tobiliary disease. MicroRNAs are emerging as
Table 1. Dog characteristics
Age (years), median
and range Sex (F, M)
ALT (U/L), median and
range (ref <70 U/L)
AP (U/L), median and
range (ref <89 U/L)
BA (lmol/L), median and
range (ref <10 lmol/L)
NL (n = 11) 5.4 (3.6–7.3) 8F, 3M 38 (23–64) 34 (14–94) 1 (0–6)
AH (n = 6) 7.3 (5.5–14.5) 5F, 1M 233 (54–845) 178 (29–1,920) 9 (1–153)
CH (n = 6) 6.4 (3.3–11.7) 5F, 1M 268 (29–2,258) 494 (23–1,200) 15 (2–112)
MU (n = 5) 8.2 (2.6–13.0) 4F, 1M 2,000 (823–4,590) 3,094 (1,019–8,305) 528 (62–660)
BI (n = 6) 9.2 (5.8–13.2) 4F, 2M 933 (408–2,700) 2,995 (208–3,850) 432 (20–1,605)
CPSS (n = 5) 0.7 (0.3–1.6) 2F, 3M 83 (22–225) 112 (103–183) 79 (19–221)
HCA (n = 6) 11.8 (6.7–15.2) 3F, 3M 837 (85–1,556) 1,548 (354–7,390) 24 (6–118)
HCC (n = 6) 9.2 (4.8–11.1) 3F, 3M 467 (42–1,300) 943 (29–4,175) 55 (5–415)
L (n = 6) 8.5 (5.4–9.9) 2F, 4M 338 (179–894) 1,375 (325–4,625) 67 (11–555)
AH, acute hepatitis; ALT, alanine aminotransferase; AP, alkaline phosphatase; BA, bile acids; BI, other biliary diseases (cholangitis or
extrahepatic bile duct obstruction); CH, chronic hepatitis; CPSS, congenital portosystemic shunts; F, female; HCA, hepatocellular ade-
noma; HCC, hepatocellular carcinoma; L, lymphoma; M, male; MU, mucoceles; NL, normal liver; ref, reference; SD, standard deviation.
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Fig 1. MicroRNA concentrations in dogs with normal livers (white) and in dogs with parenchymal (blue), biliary (yellow), vascular (red),
or neoplastic (pink) hepatobiliary disease. (A) miR-21, (B) miR-122, (C) miR-126, (D) miR-148a, (E) miR-200c, (F) miR-222. Signiﬁcant
diﬀerences between groups of hepatobiliary diseases and the normal liver group are marked with stars (*P < .05, **P < .01, ***P < .001).
AH, acute hepatitis (n = 6); BI, other biliary diseases (cholangitis or extrahepatic bile duct obstruction, n = 6); CH, chronic hepatitis
(n = 6); CPSS, congenital portosystemic shunts (n = 5); HCA, hepatocellular adenoma (n = 6); HCC, hepatocellular carcinoma (n = 6);
L, lymphoma (n = 6); Ln, natural logarithm; MU, mucoceles (n = 5); NL, normal liver (n = 11).
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biomarkers for hepatic disease because they play critical
roles in liver development and metabolism and are mea-
surable in blood even after prolonged storage.7,21,26
MicroRNAs are already evaluated as promising
biomarkers for hepatobiliary disease, including primary
hepatic tumors, in humans.8,9 In dogs, serum HDmiR-
122 and HDmiR-148a have shown to be increased upon
hepatocellular injury.27,28 In the present study, we
demonstrated diﬀerent concentrations of our selected
microRNA panel in dogs with several parenchymal, bil-
iary, and neoplastic diseases. This is the ﬁrst evidence
that a microRNA panel might be a valuable extra diag-
nostic tool, helping in diagnosing and diﬀerentiating
several common hepatobiliary diseases in dogs.
One of the diseases evaluated in this study was con-
genital portosystemic shunts. None of the microRNA
showed signiﬁcantly increased concentrations in this
group. Several studies in man and dogs demonstrated
an increase in serum miR-122 upon hepatocellular
injury.18,21,27,28 One can presume that in the case of
congenital portosystemic shunting, there is not enough
hepatocellular injury to give a rise in microRNA con-
centrations. Of all common hepatic diseases, this is the
only disease of which a presumptive diagnosis can be
made based on signalment (age, breed), clinical signs
and an ammonia tolerance test, fasting plasma ammo-
nia, fasting plasma bile acids, or bile acid stimulation
test.5,29 Therefore, microRNA proﬁling seems to be of
no added value in this group of diseases.
In dogs with hepatobiliary disease, the liver parench-
yma, gallbladder, and biliary tree can be further evalu-
ated with ultrasonography. However, in 20% of dogs
with a primary hepatitis, no abnormalities are found on
abdominal ultrasound.30 Our previous study reported
miR-122 to have a sensitivity of 84% and a speciﬁcity
of 82% in detecting dogs with hepatocellular injury.28
Results of this study indeed demonstrate an increase in
miR-122 in both dogs with acute and chronic hepatitis.
Although recent studies in humans21 and dogs28 also
showed an increase in miR-148a after hepatocellular
injury, no signiﬁcant diﬀerence in serum concentrations
was seen in the present study after correction for multi-
ple testing.
In dogs with neoplastic disease, ultrasonographic
examination of the liver can identify nodules or mass
lesions. However, it is often not possible to distinguish
between hepatocellular adenoma and carcinoma or
between neoplasms and nodular hyperplasia or cirrho-
sis.31 In case of hepatic lymphoma, the liver can appear
ultrasonographically unremarkable or hypoechoic and
diﬀusely enlarged.31,32 This emphasizes the importance
of a noninvasive microRNA panel that is able to diﬀer-
entiate between causes of hepatic lesions. Several studies
in human patients state that single serum measurements
of miR-21, miR-122, and miR-222 could not diﬀer
between hepatocellular carcinoma and hepatitis,33–35
and only one study reported that miR-21 was higher in
human patients with hepatocellular carcinoma
Fig 2. Disease-based microRNA proﬁle. Colored circles indicate relative increase in microRNA concentrations compared to the normal
liver group (n = 11). Pie charts indicate main groups of hepatic disease (parenchymal, biliary, vascular, or neoplastic diseases). Dogs with
mucoceles (MU, n = 5), hepatocellular carcinomas (HCC, n = 6), lymphomas (L, n = 6), and chronic hepatitis (CH, n = 6) all have their
own unique microRNA proﬁle. No microRNA increase is seen in dogs with adenomas (HCA, n = 6) and congenital portosystemic shunts
(CPSS, n = 5). AH, acute hepatitis (n = 6); BI, other biliary diseases (cholangitis or extrahepatic bile duct obstruction, n = 6).
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compared to patients with hepatitis.13 However, in our
study, we showed that speciﬁc microRNA concentra-
tions were increased in dogs with hepatitis and hepato-
cellular lymfomas and carcinomas. This suggests that a
panel of miR-21, miR-122, miR-126, miR-200c, and
miR-222 are possible candidates for a biomarker panel
in the discrimination of AH, CH, HCA, HCC, and L in
dogs.
One of the most important ﬁndings of this study was
the increased serum concentration of miR-200c, miR-
21, miR-222, and miR-122 in dogs with HCC. All of
these microRNAs are associated with several (human)
cancer types, especially miR-21 and miR-200c. The
miR-200 family is known to be a powerful regulator in
epithelial-to-mesenchymal transition as occurs in
embryogenesis, carcinogenesis, and remodeling
responses of adult (liver) tissue after damage.36–38 In
our study, miR-200c was only found to be increased in
the HCC group compared to controls. MicroRNA-21 is
suggested to contribute to a malignant phenotype by
exerting both antiapoptotic39 and tumor disseminating
properties.19,40Although tissue miR-126 is thought to
play critical roles in several human cancers as well,23 we
did not see any diﬀerence in serum miR-126 between
dogs with liver cancer and control dogs. This might be
because of a diﬀerence between tissue expression and
serum presence of miR-126, as serum microRNA
release does not necessarily correlate to tissue micro-
RNA expression.41 Several studies examined serum con-
centrations of miR-21, miR-122, and miR-222 in
human patients with hepatocellular carcinoma, with
similar results as our study in dogs with HCC. Four
studies identiﬁed an increase in serum miR-21 in
patients with hepatocellular carcinoma,13,33,35,42 which
is also consistent with our results, as dogs with HCC
and L had an increase in miR-21. In addition, human
patients with hepatocellular carcinoma were found to
have an increase in serum miR-12233,34 and
miR-22234,42 as well. Interestingly, in our study, none of
these microRNAs were increased in dogs with HCA,
and only miR-21 and miR-122 were increased in dogs
with L. The upregulation of miR-21, miR-122, miR-
222, and miR-200c in dogs with L or HCC compared
to controls suggests that these microRNAs can be used
as a potential biomarker for neoplastic liver disease in
dogs.
Dogs with biliary diseases usually have a marked
increase in liver enzymes, especially AP, GGT, and high
BA (Table 1).4 A future microRNA panel could help in
further diﬀerentiating underlying disease, making ori-
ented ultrasonographic examination of the hepatobiliary
tree possible. In our study, all dogs with biliary tract
diseases had high serum miR-122. This can be explained
by hepatocellular damage as a result of cholestasis, and
the subsequent release of miR-122 into serum. Further-
more, we selected miR-200c and miR-222 as CDmiRs
and therefore expected them to be increased in dogs
with biliary diseases. Only one of them, miR-222, was
increased in serum of dogs with MU. An interesting
theory that could explain this diﬀerence might be the
polarized release of CDmiRs and HDmiRs by
cholangiocytes and hepatocytes. This was recently inves-
tigated in bile and serum samples of human patients.18
Upon impaired liver function and liver injury, cholan-
giocytes release their CDmiRs into bile rather than
blood, resulting in decreased serum concentrations.
Concurrently, serum HDmiR-148a and HDmiR-122
concentrations were observed to increase upon liver cell
injury and their secretion into bile decreased. That there
are such striking diﬀerences between the MU and BI
groups is intriguing. A gallbladder mucocele is an inap-
propriate accumulation of bile-laden mucus material
occupying the gallbladder lumen. One explanation of
higher microRNA concentrations in dogs with mucoce-
les can be the higher amount of necrosis of the gallblad-
der wall and intrahepatic bile duct epithelium and thus
increased release of microRNAs into serum in dogs
with mucoceles.16,43 Another assumption of the
increased miR-21, miR-122, and miR-222 serum con-
centrations is based on one of the most important histo-
logic features of gallbladder mucoceles: hyperplasia of
the mucus-secreting glands.16,44,45 All 3 microRNAs are
known to inﬂuence cellular proliferation, cell growth,
cell cycle progression, and apoptosis, which are com-
mon features of hyperplasia.19,46,47 Diﬀerent concentra-
tions of miR-21, miR-122, and miR-222 in the two
biliary disease groups compared to the control group
again indicate that further investigations into these
microRNAs in dogs hold potential for future biomarker
development.
The results of this study are a promising new step in
the development of a biomarker proﬁle for the evalua-
tion of hepatobiliary disease in dogs. Despite the unar-
guable potential of circulating microRNAs to act as
biomarker, several points need to be addressed. To
date, even in the human literature, there is no consen-
sus about the quantiﬁcation and normalization (refer-
ence microRNAs or spike-in controls) of circulating
microRNA concentrations.48 In the veterinary ﬁeld,
microRNA expression studies are scarce, and further
studies into detection and quantiﬁcation of micro-
RNAs have to be conducted. In the present study, all
control dogs were Labrador Retrievers. As the research
of microRNAs in dogs is limited, there is nothing
known about breed-, sex-, or age-related diﬀerences of
microRNA expression in dogs. Because of the highly
conserved nature of microRNAs between species with
similar physiology,49 we do not expect microRNA con-
centrations to diﬀer between breeds. In humans, micro-
RNA concentrations have proven to be stable under
low-temperature storage conditions50,51 and over a long
period of time,52 resistant and reproducible and for
most microRNAs, there is no diﬀerence in expression
between female or male individuals.53 Although age-
related diﬀerences in humans are described, these are
mainly found comparing healthy adults with healthy
octogenarians, nonagenarians, or centenarians.54,55
Dogs in the present study are, with exception of dogs
with congenital portosystemic shunting, of comparable
age, and age-related eﬀects in microRNA concentra-
tions are therefore considered negligible. In addition,
group size in the present study was small, and to
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determine test performance of this microRNA proﬁle,
this study should be extended with larger cohorts, and
possibly more microRNA markers. Furthermore, only
HDmiR-122 has shown to be liver speciﬁc as it
accounts for 72% of all liver microRNAs with almost
no extrahepatic expression.22,56 Because all other
microRNAs lack speciﬁcity for the hepatobiliary tree,
dogs suﬀering from extrahepatic diseases, including
metastatic liver disease and dogs with nonspeciﬁc reac-
tive hepatitis, should be included in subsequent studies
to indicate speciﬁcity of this microRNA panel. In the
present study, corresponding tissue microRNA expres-
sion was not measured. At the moment, the relation-
ship between tissue and serum microRNAs remains
unclear, justifying the need for further investigations
into tissue microRNA expression and release. Based
on the study of Verhoeven et al.,18 which indicates
notable amounts of microRNAs in bile, more research
into the combination of serum and biliary microRNAs
as biomarker for hepatic disease is warranted.
In conclusion, we propose that a serum microRNA
panel might be used as a diagnostic marker for hepato-
biliary diseases in dogs and therefore can be a promis-
ing and valuable addition to the currently available
diagnostic tools. Therefore, further studies are needed
to conﬁrm these ﬁndings and to determine correspond-
ing sensitivity and speciﬁcity. In addition, further stud-
ies into the release of microRNAs in serum and bile
and the correlation with expression in liver tissue are
warranted to shed light on the role of microRNAs in
hepatic disease and their usefulness as relative noninva-
sive biomarkers in dogs.
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